Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
De-ESCALaTE HPV
ISRCTN33522080Phase 3Completed
- Sponsor
- University of Warwick
- Start
- Oct 2012
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of cetuximab and cisplatin in oropharyngeal squamous cell carcinoma (OPSCC) and head and neck cancer (HNC) (3 arms), sponsored by University of Warwick. Primary endpoint: Severe toxicity (acute and late). Started Oct 2012; status: completed.
02
Drugs
cetuximabcisplatin
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)head and neck cancer (HNC)
Beyond the preview
Go deeper on ISRCTN33522080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN33522080.